Vertex Pharmaceuticals has reported impressive fourth-quarter earnings of $3.19 billion, surpassing analyst expectations and solidifying its consistent 18.2% compound annual growth rate. As the company ramps up its investments in gene-editing therapies and expands into hematology, it has recorded a rising operating margin of 37.8%. Despite the stock currently trading at $470.31—approximately 11% below its analyst target—discussions of potential undervaluation arise, particularly as Vertex navigates the execution risks associated with its newer therapies.
“Vertex Pharmaceuticals · has delivered · compound annual growth rate (CAGR) · 18.2%”
“Vertex Pharmaceuticals · earned approval from · U.S. Food and Drug Administration for Kalydeco · 2012”
“Vertex Pharmaceuticals · could rely on · pipeline candidates · inaxaplin and povetacicept”
“Vertex Pharmaceuticals · generates · consistent revenue and earnings · thanks to its CF products”
“Vertex Pharmaceuticals · has · stock price · up”
“Vertex Pharmaceuticals · reported · fourth-quarter results · higher 2025 sales for Casgevy”
“Vertex Pharmaceuticals · makes most of its revenues by selling · approved drugs for treating cystic fibrosis · true”
“Vertex Pharmaceuticals · last closed at · US$470.31”
“Vertex Pharmaceuticals · returns over 7 days · 2.0%”
“Vertex Pharmaceuticals · returns over 30 days · 6.6%”
“Vertex Pharmaceuticals · year to date returns · 4.0%”
“Vertex Pharmaceuticals · returns over 3 years · 59.8%”